PHAT Earnings & Financial Statements
Phathom Pharmaceuticals, Inc.
$7.52
+$0.12(+1.62%)
34
Overall
40
Value
18
Tech
44
Quality
Market Cap
$598.67M
Volume
371.29K
52W Range
$6.52 - $18.31
Target Price
$20.45
PHAT earnings and financial statements: Phathom Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PHAT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $175.11M | $55.25M | $682.0K | - | - |
| Cost of revenue | $22.60M | $7.97M | $167.0K | - | - |
| Operating income | -$159.99M | -$277.47M | -$167.31M | -$172.44M | -$135.08M |
| EBITDA | -$149.49M | -$259.33M | -$203.45M | -$169.80M | -$136.57M |
| Net income | -$221.25M | -$334.33M | -$201.59M | -$197.72M | -$143.88M |
| EPS (diluted) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $259.15M | $378.32M | $413.84M | $164.81M | $189.43M |
| Total liabilities | $697.32M | $631.90M | $486.60M | $239.62M | $117.28M |
| Shareholders’ equity | -$438.17M | -$253.58M | -$72.76M | -$74.81M | $72.16M |
| Cash and equivalents | $129.97M | $297.26M | $381.39M | $155.38M | $183.26M |
| Long-term debt | $211.15M | $201.41M | $138.30M | $96.36M | $90.85M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$166.78M | -$266.77M | -$137.58M | -$146.53M | -$148.46M |
| Capital expenditure | -$229.0K | -$135.0K | -$1.63M | -$1.04M | -$328.0K |
| Free cash flow | -$167.00M | -$266.90M | -$139.21M | -$147.57M | -$148.78M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PHAT | $7.52 | +1.6% | 371.29K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Phathom Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW